Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 22, 2024
Reporting Period: Quarterly and fiscal year ended December 31, 2023.
This filing serves as a notification that the company issued a press release and an earnings presentation regarding its financial results for the period ended December 31, 2023. The detailed financial data is contained in the attached exhibits (Exhibit 99.1 and 99.2) rather than within the body of this 8-K form.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release and earnings presentation.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. It only confirms the announcement of results for the quarter and fiscal year ended December 31, 2023.
Guidance, Outlook, and Risks
Management Commentary: The company released an earnings presentation (Exhibit 99.2) which typically contains management commentary, outlook, and guidance, but the specific content is not included in this text.
Risks and Contingencies: No specific risks or contingencies are detailed in the body of this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2023.
- Examine Exhibit 99.2 (Earnings Presentation) for updated clinical trial timelines, regulatory milestones, and forward-looking guidance.
- Verify the company's cash runway and burn rate as disclosed in the full financial statements referenced in the press release.
- Check for any updates on the status of the company's primary drug candidates (e.g., Xcopri) and pipeline developments.